UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Blood, 2016-06, Vol.127 (23), p.2833-2840

2016

Volltextzugriff (PDF)

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Journal of clinical oncology, 2012-06, Vol.30 (16), p.1953-1959

2012

Volltextzugriff (PDF)

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

Journal of clinical oncology, 2012-06, Vol.30 (16), p.1960-1965

2012

Volltextzugriff (PDF)

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

The Lancet. Haematology, 2015-12, Vol.2 (12), p.e516-e527

2015

Volltextzugriff (PDF)

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Blood, 2012-07, Vol.120 (3), p.552-559

2012

Volltextzugriff (PDF)

A Case of Peeling Skin Syndrome

Indian Dermatology Online Journal, 2017-05, Vol.8 (3), p.208-210

2017

Volltextzugriff (PDF)

Cutaneous Manifestations of Chikungunya Fever: Observations from an Outbreak at a Tertiary Care Hospital in Southeast Rajasthan, India

Indian Dermatology Online Journal, 2017-09, Vol.8 (5), p.336-342

2017

Volltextzugriff (PDF)

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Blood cancer journal (New York), 2020-09, Vol.10 (9), p.91-91, Article 91

2020

Volltextzugriff (PDF)

Antitumor immunity induced by laser immunotherapy and its adoptive transfer

Cancer research (Chicago, Ill.), 2001-01, Vol.61 (2), p.459-461

2001

Volltextzugriff (PDF)

ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyl-Le(x)

Science (American Association for the Advancement of Science), 1990-11, Vol.250 (4984), p.1130-1130

1990

Volltextzugriff (PDF)

Synthetic carbohydrate vaccines based on tumour-associated antigens

Chemical Society reviews, 1995, Vol.24 (4), p.231

1995

Volltextzugriff (PDF)

Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins

Journal of the American Chemical Society, 1994-01, Vol.116 (1), p.395-396

1994

Volltextzugriff (PDF)

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8040-8040

2018

Volltextzugriff (PDF)

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8028-8028

2017

Volltextzugriff (PDF)

Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

Blood, 2015-12, Vol.126 (23), p.510-510

2015

Volltextzugriff (PDF)

Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e15-e16

2019

Volltextzugriff (PDF)

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.302-302

2014

Volltextzugriff (PDF)

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2015, Vol.33 (15_suppl), p.8508-8508

2015

Volltextzugriff (PDF)

A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8573-8573

2015

Volltextzugriff (PDF)

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8542-8542

2013

Volltextzugriff (PDF)

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens

International journal of cancer, 1997-09, Vol.73 (1), p.50-56

1997

Volltextzugriff (PDF)

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Blood, 2012-11, Vol.120 (21), p.202-202

2012

Volltextzugriff (PDF)

Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

Blood, 2011-11, Vol.118 (21), p.3968-3968

2011

Volltextzugriff (PDF)

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

Blood, 2010-11, Vol.116 (21), p.1936-1936

2010

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Englisch
(165)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

A Case of Peeling Skin Syndrome

Cutaneous Manifestations of Chikungunya Fever: Observations from an Outbreak at a Tertiary Care Hospital in Southeast Rajasthan, India

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Antitumor immunity induced by laser immunotherapy and its adoptive transfer

ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyl-Le(x)

Synthetic carbohydrate vaccines based on tumour-associated antigens

Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)

Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

Suchergebnisse filtern